Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.
Read more at The New York Times
Topics
-
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Business - MarketWatch - November 11 -
AbbVie shares tumble after schizophrenia drug disappoints
Business - Financial Times - November 11 -
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Business - MarketWatch - November 14 -
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails to meet its goals
Business - MarketWatch - Yesterday -
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
Business - MarketWatch - November 12 -
Chancellor and BoE governor call for UK to rebuild ties with EU
Business - Financial Times - November 14 -
Britain’s bold plan to create super funds
Business - Financial Times - November 14 -
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Business - MarketWatch - November 4 -
Novartis Lifts Guidance Again After Key Drugs Help Results
Business - The Wall Street Journal - October 29
More from The New York Times
-
Walmart Pulls Back on D.E.I. Initiatives Amid Conservative Pressure
Business - The New York Times - 12 hours ago -
Trump’s Tariffs Would Deal a Big Blow to the Auto Industry
Business - The New York Times - 9 hours ago -
China’s Huawei Takes Aim at Apple With Latest Smartphone
Business - The New York Times - 22 hours ago -
Macy’s Discovers Employee Hid Millions in Delivery Expenses
Business - The New York Times - Yesterday -
Yes, It ‘Looks Like a Duck,’ but Carriers Like the New Mail Truck
Business - The New York Times - 9 hours ago